title: Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: De Luca
authors.forename: Harry
authors.initials: H
authors.lastname: Suryapranata
authors.forename: Gregg W
authors.initials: GW
authors.lastname: Stone
authors.forename: David
authors.initials: D
authors.lastname: Antoniucci
authors.forename: James E
authors.initials: JE
authors.lastname: Tcheng
authors.forename: Franz-Josef
authors.initials: FJ
authors.lastname: Neumann
authors.forename: Erminio
authors.initials: E
authors.lastname: Bonizzoni
authors.forename: Eric J
authors.initials: EJ
authors.lastname: Topol
authors.forename: Massimo
authors.initials: M
authors.lastname: Chiariello
mesh_terms: D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004562:Electrocardiography; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D015996:Survival Rate
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab